Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
Corvus Pharmaceuticals (NASDAQ: CRVS) has appointed Richard van den Broek to its Board of Directors. Van den Broek, currently managing partner at HSMR Advisors, brings over 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst, and board member.
Van den Broek currently serves on the boards of Pulse Biosciences and Cogstate , and previously served on Pharmacyclics' board until its acquisition by AbbVie in 2015. He holds an A.B. degree from Harvard University and is a Chartered Financial Analyst.
The appointment aims to leverage his expertise in ITK inhibition, which Corvus is developing to modulate and control parallel signaling pathways in the immune system for treating immune diseases and cancers.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha nominato Richard van den Broek nel suo Consiglio di Amministrazione. Van den Broek, attualmente partner gestore presso HSMR Advisors, porta con sé oltre 30 anni di esperienza nell'industria delle scienze della vita come investitore, analista di ricerca azionaria nel settore biotecnologico e membro del consiglio.
Van den Broek attualmente fa parte dei consigli di amministrazione di Pulse Biosciences e Cogstate, e ha precedentemente servito nel consiglio di Pharmacyclics fino alla sua acquisizione da parte di AbbVie nel 2015. Ha conseguito una laurea A.B. presso l'Università di Harvard ed è un Chartered Financial Analyst.
La nomina mira a sfruttare la sua esperienza nell'inibizione dell'ITK, che Corvus sta sviluppando per modulare e controllare i percorsi di segnalazione paralleli nel sistema immunitario per il trattamento delle malattie immunitarie e dei tumori.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha nombrado a Richard van den Broek en su Junta Directiva. Van den Broek, actualmente socio gerente en HSMR Advisors, aporta más de 30 años de experiencia en la industria de las ciencias de la vida como inversor, analista de investigación de acciones en biotecnología y miembro de la junta.
Van den Broek actualmente forma parte de las juntas de Pulse Biosciences y Cogstate, y anteriormente sirvió en la junta de Pharmacyclics hasta su adquisición por AbbVie en 2015. Tiene un título A.B. de la Universidad de Harvard y es un Chartered Financial Analyst.
El nombramiento tiene como objetivo aprovechar su experiencia en la inhibición de ITK, que Corvus está desarrollando para modular y controlar las vías de señalización paralelas en el sistema inmunológico para tratar enfermedades inmunitarias y cánceres.
코르부스 제약 (NASDAQ: CRVS)이 리차드 반 덴 브룩을 이사회에 임명했습니다. 반 덴 브룩은 현재 HSMR 어드바이저스의 관리 파트너로, 생명 과학 산업에서 투자자, 생명공학 주식 연구 분석가 및 이사회 구성원으로서 30년 이상의 경험을 가지고 있습니다.
반 덴 브룩은 현재 Pulse Biosciences와 Cogstate의 이사회에서 활동하고 있으며, 2015년 AbbVie에 인수될 때까지 Pharmacyclics의 이사회에서도 활동했습니다. 그는 하버드 대학교에서 A.B. 학위를 취득했으며, 공인 재무 분석사입니다.
이번 임명의 목표는 코르부스가 면역 질환 및 암 치료를 위해 면역 시스템의 병렬 신호 경로를 조절하고 제어하기 위해 개발 중인 ITK 억제에 대한 그의 전문성을 활용하는 것입니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a nommé Richard van den Broek au sein de son Conseil d'Administration. Van den Broek, actuellement associé gérant chez HSMR Advisors, apporte plus de 30 ans d'expérience dans l'industrie des sciences de la vie en tant qu'investisseur, analyste de recherche sur les actions biotechnologiques et membre du conseil.
Van den Broek siège actuellement aux conseils d'administration de Pulse Biosciences et de Cogstate, et a précédemment été membre du conseil de Pharmacyclics jusqu'à son acquisition par AbbVie en 2015. Il est titulaire d'un diplôme A.B. de l'Université de Harvard et est Chartered Financial Analyst.
Cette nomination vise à tirer parti de son expertise en inhibition de l'ITK, que Corvus développe pour moduler et contrôler les voies de signalisation parallèles dans le système immunitaire pour traiter les maladies immunitaires et les cancers.
Corvus Pharmaceuticals (NASDAQ: CRVS) hat Richard van den Broek in seinen Vorstand berufen. Van den Broek, der derzeit Managing Partner bei HSMR Advisors ist, bringt über 30 Jahre Erfahrung in der Lebenswissenschaftsbranche als Investor, Biotechnologie-Aktienanalyst und Vorstandsmitglied mit.
Van den Broek ist derzeit Mitglied der Aufsichtsräte von Pulse Biosciences und Cogstate und war zuvor bis zur Übernahme durch AbbVie im Jahr 2015 im Vorstand von Pharmacyclics tätig. Er hat einen A.B.-Abschluss von der Harvard-Universität und ist Chartered Financial Analyst.
Die Ernennung zielt darauf ab, seine Expertise in der ITK-Hemmung zu nutzen, die Corvus entwickelt, um parallele Signalwege im Immunsystem zur Behandlung von Immunerkrankungen und Krebs zu modulieren und zu steuern.
- Addition of board member with extensive biotech industry experience and successful track record
- New director brings specific expertise in ITK inhibition development from Pharmacyclics success
- Strategic appointment aligns with company's focus on immune system pathway modulation
- None.
SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member.
“We’re thrilled to welcome Richard to our board,” said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. “Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutical market. We look forward to working with Richard as we continue to advance ITK inhibition and the unique opportunity it provides to modulate and control parallel signaling pathways in the immune system.”
“I am honored to join the Corvus board of directors as the Company continues to advance its clinical pipeline,” said Mr. van den Broek. “I believe ITK inhibition represents a significant opportunity to improve the lives of patients with immune diseases and cancers, similar to my experience on the board at Pharmacyclics where using a similar strategy, we brought the first BTK inhibitor to market for the treatment of lymphomas and then immune diseases.”
Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and has served as a director of Pulse Biosciences, Inc since 2020 and Cogstate Ltd since 2009. Mr. van den Broek previously served on the board of directors of Pharmacyclics, Inc. from December 2009 through its acquisition by AbbVie, announced in March 2015. Mr. van den Broek received an A.B. degree from Harvard University and is a Chartered Financial Analyst.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements related to the potential of the Company’s product candidates including soquelitinib, the advancement of ITK inhibition and the opportunities it provides, continued advancement of the Company’s clinical pipeline, and Mr. van den Broek’s expected contributions to the Company’s board of directors. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 25, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient number of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
Who is Richard van den Broek and what experience does he bring to CRVS board?
What is Corvus Pharmaceuticals' (CRVS) current focus in drug development?
What other board positions does Richard van den Broek currently hold?
What was Richard van den Broek's role in Pharmacyclics before its acquisition?
